Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 18/20 | 0.62 |
| ▸ | MMP13 | P45452 | 18/20 | 0.62 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 2/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772246 | 0.99 | MMP1 (0.62) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6770734 | 0.88 | USP2 (0.56) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6964498 | 0.86 | MMP1 (0.79) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6766379 | 0.86 | USP2 (0.54) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL12418068 | 0.85 | MMP1 (0.47) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6965873 | 0.84 | MMP1 (0.79) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7064268 | 0.83 | HTT (0.60) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL12418064 | 0.83 | MMP1 (0.47) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6962211 | 0.81 | MMP1 (0.83) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6960331 | 0.80 | MMP1 (0.72) | MMP1MMP13MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210326-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2001012592-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-02-22 | — | — | WO | claimed |
| US-9616037-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2017-04-11 | — | — | US | disclosed |
| US-9616037-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2017-04-11 | — | — | US | disclosed |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-9302984-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-9302984-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-09-24 | — | — | US | disclosed |
| US-9050329-B1 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20150141472-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| EP-2344449-B1 | ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8822507-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2014-09-02 | — | — | US | disclosed |
| US-20130245018-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (US) | 2013-09-19 | — | — | US | disclosed |
| US-8435968-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20110172189-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| US-6677355-B1 | DIBENZOFURAN-3-(SULFONYLAMINO OR SULFINAMINO) DERIVATIVES; MULTIPLE SCLEROSIS, ATHEROSCLEROSIS, HEART FAILURE, PERIODONTAL DISEASE, OSTEOARTHRITIS, AUTOIMMUNE DISEASE; ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2004-01-13 | — | — | US | disclosed |
| EP-1210326-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012592-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172189-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | MMP1 1798/4885MMP13 898/4885MMP2 2247/4885 |
| US-20150141472-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | MMP1 1981/4885MMP13 940/4885MMP2 2411/4885 |
| US-20130245018-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | MMP1 1981/4885MMP13 940/4885MMP2 2411/4885 |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | MMP1 1981/4885MMP13 940/4885MMP2 2411/4885 |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | MMP1 1981/4885MMP13 940/4885MMP2 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.